Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells

Hong Seok Park, Sung Kyu Hong, Mi-Mi Oh, Cheol Yong Yoon, Seong Jin Jeong, Seok Soo Byun, Jun Cheon, Sang Eun Lee, Du Geon Moon

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

According to recent studies, mTOR (mammalian target of rapamycin) inhibitor and tyrosine kinase inhibitor (TKI) can be used as combinational agents to enhance the antitumor effect or overcome resistance to one of the agents. In the present study, we investigated the synergistic interaction between NVP-BEZ235, a PI3K (phosphoinositide 3-kinase)/mTOR dual inhibitor, and sunitinib, a TKI, in castration-resistant prostate cancer (CRPC) cells with docetaxel resistance. Prostate cancer cells with different sensitivities to hormones and docetaxel levels were exposed to escalating doses of NVP-BEZ235 alone and in combination with sunitinib. The synergy between NVP-BEZ235 and sunitinib was determined by the combination index, threedimensional model, and clonogenic assays. Flow cytometry and western blot analysis of proteins related to apoptosis and cell survival axis were performed. The combination of NVPBEZ235 and sunitinib caused a significant synergistic antitumor effect over a wide range of doses in docetaxelresistant CRPC cells. Furthermore, the IC50 (half-maximal inhibitory concentration) of NVP-BEZ235 and sunitinib was reduced by 7.8-fold and 6.6-fold, respectively. The three-dimensional synergy analysis resulted in a synergy volume of 182.47 μM/ml2%, indicating a strong synergistic effect of combination therapy. Combination therapy caused an induction of caspase-dependent apoptosis in docetaxelresistant CRPC cells. Adding sunitinib did not produce any additional effect on the NVP-BEZ235-mediated inhibition of PI3K/AKT/mTOR phosphorylation. In conclusion, combining NVP-BEZ235, a dual PI3K/mTOR inhibitor, with sunitinib can synergistically potentiate the antitumor effect in CRPC cells after docetaxel failure though induction of caspase-dependent apoptosis.

Original languageEnglish
Pages (from-to)3457-3468
Number of pages12
JournalAnticancer Research
Volume34
Issue number7
Publication statusPublished - 2014 Jan 1

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Sirolimus
1-Phosphatidylinositol 4-Kinase
Apoptosis
Caspases
Protein-Tyrosine Kinases
sunitinib
dactolisib
Inhibitory Concentration 50
Cell Survival
Flow Cytometry

Keywords

  • Carcinoma
  • Docetaxel
  • NVPBEZ235
  • Prostate
  • Resistance
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. / Park, Hong Seok; Hong, Sung Kyu; Oh, Mi-Mi; Yoon, Cheol Yong; Jeong, Seong Jin; Byun, Seok Soo; Cheon, Jun; Lee, Sang Eun; Moon, Du Geon.

In: Anticancer Research, Vol. 34, No. 7, 01.01.2014, p. 3457-3468.

Research output: Contribution to journalArticle

Park, Hong Seok ; Hong, Sung Kyu ; Oh, Mi-Mi ; Yoon, Cheol Yong ; Jeong, Seong Jin ; Byun, Seok Soo ; Cheon, Jun ; Lee, Sang Eun ; Moon, Du Geon. / Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. In: Anticancer Research. 2014 ; Vol. 34, No. 7. pp. 3457-3468.
@article{68485554608746c4881dcf19c1ef1800,
title = "Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells",
abstract = "According to recent studies, mTOR (mammalian target of rapamycin) inhibitor and tyrosine kinase inhibitor (TKI) can be used as combinational agents to enhance the antitumor effect or overcome resistance to one of the agents. In the present study, we investigated the synergistic interaction between NVP-BEZ235, a PI3K (phosphoinositide 3-kinase)/mTOR dual inhibitor, and sunitinib, a TKI, in castration-resistant prostate cancer (CRPC) cells with docetaxel resistance. Prostate cancer cells with different sensitivities to hormones and docetaxel levels were exposed to escalating doses of NVP-BEZ235 alone and in combination with sunitinib. The synergy between NVP-BEZ235 and sunitinib was determined by the combination index, threedimensional model, and clonogenic assays. Flow cytometry and western blot analysis of proteins related to apoptosis and cell survival axis were performed. The combination of NVPBEZ235 and sunitinib caused a significant synergistic antitumor effect over a wide range of doses in docetaxelresistant CRPC cells. Furthermore, the IC50 (half-maximal inhibitory concentration) of NVP-BEZ235 and sunitinib was reduced by 7.8-fold and 6.6-fold, respectively. The three-dimensional synergy analysis resulted in a synergy volume of 182.47 μM/ml2{\%}, indicating a strong synergistic effect of combination therapy. Combination therapy caused an induction of caspase-dependent apoptosis in docetaxelresistant CRPC cells. Adding sunitinib did not produce any additional effect on the NVP-BEZ235-mediated inhibition of PI3K/AKT/mTOR phosphorylation. In conclusion, combining NVP-BEZ235, a dual PI3K/mTOR inhibitor, with sunitinib can synergistically potentiate the antitumor effect in CRPC cells after docetaxel failure though induction of caspase-dependent apoptosis.",
keywords = "Carcinoma, Docetaxel, NVPBEZ235, Prostate, Resistance, Sunitinib",
author = "Park, {Hong Seok} and Hong, {Sung Kyu} and Mi-Mi Oh and Yoon, {Cheol Yong} and Jeong, {Seong Jin} and Byun, {Seok Soo} and Jun Cheon and Lee, {Sang Eun} and Moon, {Du Geon}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "3457--3468",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells

AU - Park, Hong Seok

AU - Hong, Sung Kyu

AU - Oh, Mi-Mi

AU - Yoon, Cheol Yong

AU - Jeong, Seong Jin

AU - Byun, Seok Soo

AU - Cheon, Jun

AU - Lee, Sang Eun

AU - Moon, Du Geon

PY - 2014/1/1

Y1 - 2014/1/1

N2 - According to recent studies, mTOR (mammalian target of rapamycin) inhibitor and tyrosine kinase inhibitor (TKI) can be used as combinational agents to enhance the antitumor effect or overcome resistance to one of the agents. In the present study, we investigated the synergistic interaction between NVP-BEZ235, a PI3K (phosphoinositide 3-kinase)/mTOR dual inhibitor, and sunitinib, a TKI, in castration-resistant prostate cancer (CRPC) cells with docetaxel resistance. Prostate cancer cells with different sensitivities to hormones and docetaxel levels were exposed to escalating doses of NVP-BEZ235 alone and in combination with sunitinib. The synergy between NVP-BEZ235 and sunitinib was determined by the combination index, threedimensional model, and clonogenic assays. Flow cytometry and western blot analysis of proteins related to apoptosis and cell survival axis were performed. The combination of NVPBEZ235 and sunitinib caused a significant synergistic antitumor effect over a wide range of doses in docetaxelresistant CRPC cells. Furthermore, the IC50 (half-maximal inhibitory concentration) of NVP-BEZ235 and sunitinib was reduced by 7.8-fold and 6.6-fold, respectively. The three-dimensional synergy analysis resulted in a synergy volume of 182.47 μM/ml2%, indicating a strong synergistic effect of combination therapy. Combination therapy caused an induction of caspase-dependent apoptosis in docetaxelresistant CRPC cells. Adding sunitinib did not produce any additional effect on the NVP-BEZ235-mediated inhibition of PI3K/AKT/mTOR phosphorylation. In conclusion, combining NVP-BEZ235, a dual PI3K/mTOR inhibitor, with sunitinib can synergistically potentiate the antitumor effect in CRPC cells after docetaxel failure though induction of caspase-dependent apoptosis.

AB - According to recent studies, mTOR (mammalian target of rapamycin) inhibitor and tyrosine kinase inhibitor (TKI) can be used as combinational agents to enhance the antitumor effect or overcome resistance to one of the agents. In the present study, we investigated the synergistic interaction between NVP-BEZ235, a PI3K (phosphoinositide 3-kinase)/mTOR dual inhibitor, and sunitinib, a TKI, in castration-resistant prostate cancer (CRPC) cells with docetaxel resistance. Prostate cancer cells with different sensitivities to hormones and docetaxel levels were exposed to escalating doses of NVP-BEZ235 alone and in combination with sunitinib. The synergy between NVP-BEZ235 and sunitinib was determined by the combination index, threedimensional model, and clonogenic assays. Flow cytometry and western blot analysis of proteins related to apoptosis and cell survival axis were performed. The combination of NVPBEZ235 and sunitinib caused a significant synergistic antitumor effect over a wide range of doses in docetaxelresistant CRPC cells. Furthermore, the IC50 (half-maximal inhibitory concentration) of NVP-BEZ235 and sunitinib was reduced by 7.8-fold and 6.6-fold, respectively. The three-dimensional synergy analysis resulted in a synergy volume of 182.47 μM/ml2%, indicating a strong synergistic effect of combination therapy. Combination therapy caused an induction of caspase-dependent apoptosis in docetaxelresistant CRPC cells. Adding sunitinib did not produce any additional effect on the NVP-BEZ235-mediated inhibition of PI3K/AKT/mTOR phosphorylation. In conclusion, combining NVP-BEZ235, a dual PI3K/mTOR inhibitor, with sunitinib can synergistically potentiate the antitumor effect in CRPC cells after docetaxel failure though induction of caspase-dependent apoptosis.

KW - Carcinoma

KW - Docetaxel

KW - NVPBEZ235

KW - Prostate

KW - Resistance

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84906321821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906321821&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 3457

EP - 3468

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -